Calcium Channel Blocker Toxicity

Etiology

Accidental overdose, suicidal ingestion, and exploratory ingestion in children can lead to severe toxicity. Therapeutic use may result in toxicity secondary to drug interactions with other cardiovascular agents or increased drug exposure due to impaired metabolism or elimination. CCB poisoning may produce severe hemodynamic compromise and can be fatal.[1]

Epidemiology

Data from America’s Poison Centers demonstrate that CCBs accounted for the highest number of fatalities among reported cases involving cardiovascular medications, with 193 deaths in 2023. Comparatively, β-blockers and miscellaneous cardiovascular drugs accounted for 125 and 85 fatalities, respectively. Amlodipine and diltiazem were most commonly implicated in fatal exposures.[2] Underreporting remains a recognized limitation of poison center data.

Pathophysiology

All currently available CCBs share a common primary mechanism of action: antagonism of L-type voltage-gated calcium channels. These ion channels are distributed in the heart, vascular smooth muscle, and pancreas. Knowledge of channel distribution and site-specific calcium physiology helps explain the clinical toxidrome associated with CCB toxicity.

Calcium influx is essential for spontaneous depolarization in sinoatrial node pacemaker cells and for impulse conduction through the atrioventricular node. Calcium gradients are critical for function in all muscle tissue. Skeletal muscle depends primarily on intracellular calcium stores, whereas cardiac and smooth muscle rely on extracellular calcium influx. Intracellular calcium entry initiates downstream signaling cascades that result in muscle contraction.

Toxicokinetics

All CCBs demonstrate high oral bioavailability across subclasses and undergo extensive hepatic 1st-pass metabolism. CCBs are highly lipophilic, exhibit strong plasma protein binding, and possess a large volume of distribution (> 2 liters/kg), rendering hemodialysis and hemofiltration largely ineffective for drug removal. The EXtracorporeal Treatments in Poisoning (EXTRIP) workgroup found no clinical benefit in available clinical or dialyzability data to support the use of extracorporeal treatments in CCB toxicity.[3]

Metabolism becomes saturated with increased or repeated dosing due to limited hepatic enzymatic capacity.[4] Coadministration with agents that inhibit or induce hepatic enzymes may produce clinically significant drug–drug interactions and increase the risk of toxicity.

Two major CCB subclasses are recognized based on predominant physiologic effects on cardiac tissue and vascular smooth muscle: dihydropyridines and nondihydropyridines. Dihydropyridines include nifedipine, amlodipine, felodipine, isradipine, nicardipine, and nimodipine. Nondihydropyridines include verapamil (phenylalkylamine class) and diltiazem (benzothiazepine class).

Verapamil demonstrates a high affinity for both myocardial tissue and vascular smooth muscle. The drug suppresses cardiac contractility, sinoatrial node automaticity, and atrioventricular nodal conduction and induces peripheral vasodilation. Diltiazem produces a similar spectrum of effects with less vasodilation and greater relative chronotropic effect.[5] Dihydropyridines act as potent vasodilators with comparatively limited effects on cardiac pacemaker activity and myocardial contractility.[6]

In a significant overdose, serum and tissue concentrations may become sufficiently elevated that subclass selectivity is lost. Therefore, verapamil and diltiazem toxicity may produce marked bradycardia, hypotension, conduction disturbances, and escape rhythms. Dihydropyridine toxicity may produce reflex sinus tachycardia at therapeutic and moderately supratherapeutic doses.[7]

CCBs of all subclasses reduce pancreatic insulin secretion and promote peripheral insulin resistance, resulting in hyperglycemia. This condition has been proposed as a prognostic indicator of poisoning severity, particularly in nondihydropyridine CCB toxicity.[8][9]

History and Physical

CCB toxicity is typically characterized by hypotension and bradycardia, which arise from a combination of peripheral vasodilation and decreased myocardial inotropy. Clinical presentation may vary, depending on dose ingested, time since ingestion, formulation (immediate-release versus extended- or sustained-release), any coingested medications, and underlying comorbidities. Patients may be asymptomatic or develop nonspecific symptoms, such as dizziness or fatigue, followed by rapid progression to hemodynamic instability and shock. Asymptomatic patients warrant an observation period of up to 24 hours, particularly after ingestion of a potentially toxic dose of a sustained-release formulation.[10]

In symptomatic individuals, findings beyond hypotension and bradycardia may include nausea, vomiting, metabolic acidosis secondary to hypoperfusion, and hyperglycemia due to impaired pancreatic insulin release. Severe poisoning may also involve noncardiogenic pulmonary edema. The underlying mechanism is incompletely understood but is presumed to involve rapid precapillary vasodilation with increased transcapillary hydrostatic pressure.[11]

Evaluation

All patients presenting with concern for CCB toxicity should undergo initial vital sign assessment and continuous cardiac monitoring throughout evaluation. Electrocardiography (ECG) should be obtained to assess for conduction abnormalities. Cardiac conduction disturbances are more commonly associated with nondihydropyridine overdoses and include sinus bradycardia, varying degrees of atrioventricular block, complete heart block, and junctional rhythms. Dihydropyridine overdoses may also produce reflex tachycardia.[12]

Basic laboratory studies should be obtained, and evaluation for potential coingestants, such as acetaminophen or salicylates, may be warranted when clinically indicated. Routine toxicology screens do not typically include CCBs, and quantitative assays are not readily available to bedside clinicians.

Bedside echocardiography may be useful in patients with hemodynamic compromise to assess cardiac function and the presence of peripheral vasodilation. Echocardiography may also assist in guiding therapy and evaluating response to interventions.

Treatment / Management

Initial Management

Stabilization of patients with suspected CCB poisoning follows the fundamental principles of critical care. Aggressive supportive therapy is prioritized, with emphasis on maintenance of circulation to preserve end-organ perfusion.

Endotracheal intubation should be considered in patients with worsening toxicity due to the risk of rapid hemodynamic deterioration. Some experts advocate preadministration of atropine to mitigate vagally mediated hypotension and bradycardia during laryngoscopy.

History should focus on underlying comorbidities, formulation ingested (immediate-release versus sustained-release), possible coingestants, and time of ingestion. Continuous telemetry monitoring is required for all patients, with consideration of invasive hemodynamic monitoring in severe cases. An ECG should be obtained promptly to identify conduction abnormalities.

Initial resuscitation should include intravenous crystalloid administration, with caution regarding potential fluid overload in the setting of drug-induced myocardial depression. Dynamic assessment of fluid responsiveness using pulse pressure variation or stroke volume variation may be useful.

Early consultation with a medical toxicologist or poison control center is strongly recommended. Available institutional resources, including intensive care capability and extracorporeal membrane oxygenation (ECMO) support, should be assessed promptly. Transfer to a tertiary care facility may be indicated following initial stabilization when advanced resources are unavailable.

Gastrointestinal Decontamination

Early intervention with gastrointestinal decontamination, particularly in sustained-release ingestions, is recommended. However, the clinical utility of this measure is controversial due to a lack of clear survival benefit.[13] Gastrointestinal decontamination should not take precedence over resuscitative efforts and should be reserved for appropriate patients, including those with intact mental status and no risk of airway compromise.(A1)

Activated charcoal should be administered at a dose of 1 g/kg within 1 to 2 hours of ingestion for optimal effect.[14][15][16] Multidose activated charcoal may be continued at a dose of 0.5 g/kg every 2 to 4 hours, provided bowel function is adequate.(A1)

Whole bowel irrigation (WBI) may be considered in cases of massive overdose or ingestion of sustained- or extended-release formulations. WBI may be administered via the oral route or a nasogastric tube. WBI is contraindicated in patients with evidence of impaired bowel function or hemodynamic instability, as risks may outweigh potential benefits.[17]

Pharmacological Therapies

Pharmacologic management of severe toxicity involves several adjunctive therapies directed at restoring perfusion and supporting cardiac function. Selection of therapy should be guided by the dominant hemodynamic disturbance and severity of clinical presentation.

Atropine

Atropine injection is a reasonable initial intervention in patients with symptomatic bradycardia due to widespread familiarity and ready availability.[18] However, studies have demonstrated limited efficacy in cases of severe poisoning.[19] Atropine dosing follows Advanced Cardiac Life Support recommendations. In adults, 0.5 to 1.0 mg is administered intravenously every 2 to 3 minutes, with a maximum total dose of 3 mg.(B3)

Calcium

The rationale for calcium administration is that increased extracellular calcium concentration promotes calcium influx through unblocked L-type calcium channels. Calcium administration may improve hypotension and contractility but is less effective for conduction disturbances and bradycardia.[20][21] Clinical response is variable in practice.[22][23]

Calcium chloride and calcium gluconate are both acceptable formulations. While considered equally efficacious, 1 g of calcium chloride contains nearly 3 times the elemental calcium compared with 1 g of calcium gluconate, ie, 1 g of calcium chloride contains 13.6 mEq of calcium versus 4.5 mEq of calcium in 1 g of calcium gluconate. The initial recommended dose is 10 to 20 mL of 10% calcium chloride (30 to 60 mL for calcium gluconate), with repeat bolus injection or initiation of a continuous infusion as needed.

A key limitation of calcium chloride is the risk of dermal necrosis with extravasation. Administration via central venous access is preferred. Calcium gluconate is safe for peripheral administration. Adverse effects, including rare fatalities, have been reported and are possibly secondary to iatrogenic hypercalcemia.[24][25] (B3)

Vasopressors

Catecholamine support should be considered in cases refractory to initial 1st-line measures, although no inotrope or vasopressor has demonstrated consistent efficacy. The selection of an agent should be guided by clinical assessment of shock physiology (cardiogenic versus vasoplegic). Point-of-care cardiac ultrasound may be particularly useful in guiding vasopressor selection. Epinephrine is recommended to improve contractility and heart rate, whereas norepinephrine is preferred when vasoplegic shock has occurred or myocardial function has not yet been assessed. A retrospective study spanning 25 years found that vasopressor use in nondihydropyridine toxicity (without concurrent high-dose insulin therapy) was associated with favorable clinical outcomes and few ischemic complications, despite use of higher-than-standard infusion doses.[26] Vasopressor support has also demonstrated benefit in dihydropyridine poisoning. Higher doses and combination therapy are often required, and ischemic complications are uncommon.[27](B2)

Hyperinsulinemic euglycemia

Hyperinsulinemic euglycemia therapy (HIET), also referred to as "high-dose insulin therapy," has emerged as a treatment for severe CCB toxicity. Experimental models demonstrate a shift in myocardial substrate utilization from free fatty acids to carbohydrates in CCB toxicity. Concurrently, CCB toxicity impairs carbohydrate utilization through reduced insulin secretion, development of insulin resistance, and interference with glucose catabolism.[28] Animal studies and human case reports demonstrate improved contractility and blood pressure following insulin therapy in CCB toxicity.[29][30][31] Insulin also exhibits vasodilatory properties. The positive inotropic effects of HIET may be insufficient in dihydropyridine toxicity, particularly in cases of amlodipine-induced vasoplegic shock, and vasodilatory effects may be detrimental.[32] Treatment should be individualized based on the clinical presentation and hemodynamic profile.(B3)

Close monitoring for hypoglycemia and hypokalemia is required when HIET is initiated, although these electrolyte disturbances are not associated with adverse sequelae when appropriately managed.[33] Blood glucose and potassium levels should be assessed before starting insulin therapy. Concurrent dextrose administration and potassium supplementation are required if the blood glucose level is below 200 mg/dL, and potassium is less than 2.5 mEq/L. HIET should be initiated with an intravenous bolus of regular insulin at 1 unit/kg, followed by a continuous infusion of 1 to 10 units/kg/hour, titrated to evidence of improved perfusion. After initiation, glucose monitoring should occur every 10 minutes, then every 30 to 45 minutes once stable, with a target of euglycemia. A delay exists between HIET initiation and clinical effect. Early initiation is recommended, with other therapies continued in the interim.

Glucagon

In normal physiology, glucagon is a polypeptide hormone secreted by pancreatic α cells. This polypeptide exerts its effects through activation of adenylate cyclase via G proteins, resulting in positive chronotropic and inotropic effects.[34] Human data regarding efficacy in CCB toxicity are lacking. However, animal models demonstrate increased heart rate, improved cardiac output, and partial reversal of atrioventricular block following glucagon administration.[35] An initial dose of 3 to 5 mg administered slowly over 3 to 5 minutes is reasonable. Clinical improvement in heart rate, if present, is typically observed within minutes. The polypeptide’s short duration of action often necessitates repeated dosing, and additional doses of 5 to 10 mg may be given if no therapeutic response is achieved. Maintenance infusion may be considered, though tachyphylaxis may develop with continued administration. Adverse effects include vomiting and hyperglycemia. Antiemetic premedication may reduce glucagon-associated nausea.(A1)

Methylene blue

Methylene blue inhibits guanylate cyclase, resulting in decreased cyclic guanosine monophosphate (cGMP) levels. Methylene blue also scavenges nitric oxide and inhibits nitric oxide synthesis. Nitric oxide and cGMP are key mediators of vascular tone and vasodilation.[36] Although not routinely recommended, methylene blue has been used as an adjunct in CCB overdose with refractory shock in select case reports and animal models. No standardized dosing strategy has been established. However, a systematic review of methylene blue administration for drug-induced shock reported most cases using methemoglobinemia dosing of 1 to 2 mg/kg.[37] Transient pulse oximetry alterations and bluish discoloration of urine, saliva, and skin may occur following administration.(A1)

Lipid emulsion therapy

Intravenous lipid emulsion is an oil-in-water emulsion that generates an intravascular lipid phase, facilitating sequestration of lipophilic drugs and reducing effective distribution. A case report of verapamil overdose demonstrated a reduction in serum drug concentration following lipid emulsion administration, supporting the lipid sink hypothesis.[38] Clinical outcomes are inconsistent, and routine use is not recommended. Intravenous lipid emulsion may be considered in patients experiencing cardiac arrest or periarrest who have failed maximal conventional therapies and in whom extracorporeal life support is not available.[39]

Other pharmacologic agents

Other pharmacotherapies, including levosimendan and 4-aminopyridine administration, have been studied in CCB toxicity. Available evidence remains insufficient to support routine clinical use of these agents.

Extracorporeal Life Support

A growing body of evidence supports the use of venoarterial ECMO in patients with refractory cardiogenic shock due to toxic exposure. A recent narrative review suggests reduced mortality among patients treated with ECMO compared with those of similar illness severity not given this intervention.[40](B3)

Differential Diagnosis

While bradycardia and hypotension are defining features of CCB poisoning, similar clinical presentations may occur with other pharmacologic toxicities. Differential diagnosis should include poisoning from β-adrenergic antagonists, cardioactive steroids, α2-agonists, opioids, and sedative-hypnotics.

Prognosis

Patient outcome is multifactorial. The prognosis depends on the presence of underlying comorbidities, the magnitude of ingestion, the severity of poisoning, and the extent of organ dysfunction.

Complications

Complications may arise from the poisoning itself or the sequelae of therapeutic interventions. Particular risk is associated with vasopressor administration and calcium infusions as described above.